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Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson’s disease (PD). This open-label pilot
study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported
sleep complaints. 15 PDpatients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which
was titrated to the dose subjectively improving motor symptoms (4–8mg/24 h). Sleep disturbances, daytime sleepiness, cognitive
performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction
in nocturnal motor activity andmean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline.
In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency≤ 85%), rotigotine also significantly improved
other sleep parameters and further reduced nocturnal motor activity andmean duration of wake episodes. A significant decrease in
number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves
perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement
of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-
observational study registry number 12021.
1. Introduction
Sleep disturbances represent independent and important
predictors of poor quality of life (QoL) in Parkinson’s disease
(PD) [1, 2].
Reduced sleep efficiency, arousal, and sleep fragmen-
tation may be caused by PD pathology, motor symptoms
(e.g., akinesia, rigidity, and dystonia), autonomic symptoms
(nocturia), or a coexisting sleep disorder (e.g., restless legs
syndrome, RLS; REM sleep behavior disorder, RBD). In addi-
tion patients could complain of excessive daytime sleepiness
(EDS), increased diurnal sleep episodes, or sudden sleep
attacks that have been related to nocturnal sleep disturbances,
PDpathology, or use of dopaminergic agents [3].The latter on
the other hand were also demonstrated to improve sleep in
PD. Rotigotine, a dopamine agonist available as transdermal
patch and providing 24 hours (h) of drug delivery, was shown
to subjectively improve sleep disturbances in PD patients [4–
6]. However, an objective evaluation of this effect is lacking.
Actigraphy is routinely used to evaluate the sleep-wake
cycle for long periods, through a portable device usually worn
on the wrist using an accelerometer to detect movement,
which is sampled several times a second. The accelerometer
generates a voltage during each movement, which is ampli-
fied and band-pass filtered (2-3Hz). The resulting signal is
compared with a reference signal to determine if it exceeds
a threshold for quantification and storage. Computerized
scoring algorithms then qualified epoch of time (i.e., 60
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seconds) as wake or sleep by comparing the activity score
expressed in counts for that epoch to a threshold of activity
set by the users. The motor activity is also quantified and
reported as mean or median value of activity per epoch (or
per minute for epoch of 60 seconds) [7]. In PD patients
actigraphy proved appropriate to assess sleep quality, well
correlating with subjective sleep measurements [8].
This open-label pilot study aimed to evaluate rotigotine’s
effect on sleep in PD patients with self-reported sleep com-
plaints, providing also objective measurements by means of
actigraphic recording.
2. Material and Methods
2.1. Selection of Patients. BetweenApril 2013 and June 2014we
recruited from the outpatient Movement Disorders Clinic of
our department 15 consecutive PD patients [1] who reported
sleep complaints and showed a PD Sleep Scale-2 (PDSS-
2) score ≥ 10 [9]. Only patients with a Hoehn and Yahr
(H&Y) Score ≤ 3 [10], free from any medication for PD or
treated with immediate-release levodopa (LD) and/or with
the monoamine oxidase inhibitor rasagiline or selegiline on
a stable dose for at least 4 weeks, requiring rotigotine to
improve motor symptoms, were eligible. Exclusion criteria to
enter the study were as follows: (1) global cognitive decline
defined by aMiniMental State Exam (MMSE) score < 24 [11];
(2) orthostatic hypotension [12]; (3) diagnosis of obstructive
sleep apnea syndrome bymeans of Berlin Questionnaire [13];
(4) any clinically severe medical or psychiatric disease that
could have interfered with study results; (5) concomitant
treatment with drugs impacting sleep with the exception of
benzodiazepines or selective serotonin reuptake inhibitors at
low dose and stable for at least 6 months prior to enrollment.
The study was approved by the local ethics committee
(AUSL of Bologna) and performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and subsequent amendments. Patients gave written
informed consent before entering the study.
2.2. Protocol. Within 1 week after the screening, patients
underwent the baseline visit (T0) including the following:
(1) history taking, neurological examination, and blood
pressure measurement to exclude orthostatic hypotension
[12]; (2) quantification of motor impairment and disease
severity (Unified PD Rating Scale-part III (UPDRS-III) and
H&Y Score) [14]; (3) evaluation of sleep disturbances and
daytime sleepiness by means of PDSS-2, RLS criteria and
RLS rating scale, RBD questionnaire, and Epworth Sleep
Scale (ESS) [15–17]; (4) PD Questionnaire-39 (PDQ-39)
and Beck Depression Inventory (BDI) to assess QoL and
depression [18, 19]; (5) global cognitive evaluation through
MMSE [11]; (6) one-week wrist actigraphic recording (Mini
Motionlogger Actigraph Advanced; Ambulatory Monitoring
Inc., New York, NY, USA) with concurrent subjective sleep
diary compilation. The portable device was worn on the
nondominant wrist or on the unaffected arm in patients with
resting arm tremor.The Cole-Kripke algorithm (with rescore
options) was used to score the actigraphic data (Action-W
version 2.7) [20]. Actigraphic measures during the nocturnal
period (from lights off to lights on as stated on the sleep
diary) included the following: sleep latency to persistent
sleep (SL, latency in min of the first continuous block of at
least 20min sleep from the marked “lights-off” time); total
sleep time (TST, overall min of sleep during the nocturnal
recording); sleep efficiency (SE, TST/total recording time in
percentage); activity mean (ACmean, mean activity score in
counts/min); activity median (ACmedian, median activity
score in counts/min); activity index (ACindex, percentage
of TST with activity score > 0); total duration of wake time
after sleep onset (WASO); number of wake episodes (number
of periods of contiguous wakefulness epochs of 60 seconds)
and mean duration of wake episodes. For the diurnal period
(the remaining time of the 24 hr cycle after the exclusion of
the nocturnal period) number and duration of sleep episodes
were calculated. The sleep diary outcomes were the number
of good sleep nights/week, the subjective estimation of the
number and duration of nocturnal awakenings and of diurnal
sleep episodes.
At the end of the actigraphic recording patients received
rotigotine 24 h transdermal patch, which was titrated over 1–
4 weeks to the optimal dose to subjectively improve motor
symptoms, starting at 2mg/24 h with weekly increments of
2mg/24 h up to a maximum of 8mg/24 h. The final dose
was maintained for 4 weeks. The occurrence of rotigotine
related adverse events and the emergence of impulse control
disorders were monitored with weekly phone calls and
additional visits when required.
When adverse events occurred during the titration
period, rotigotine dose was back-titrated to the previous
tolerated dose for the maintenance period. At the end of
the maintenance period patients underwent a new visit (T1)
including the same assessment performed at T0.
2.3. Statistical Analysis. Rotigotine’s effect on sleep distur-
bances was evaluated by comparing actigraphic data, sleep
diary, and questionnaire results obtained at T1 and T0. Mean
values of 7 days were calculated for each parameter for
statistical analysis.
Questionnaires and scales on motor performance, QoL,
depression, and global cognitive profile were also compared
between T1 and T0.
As deviation from a normal distribution was found data
were reported as medians and 25th–75th percentiles and
comparisons performed by the Wilcoxon signed-rank test.
Statistical significance was set at 𝑝 ≤ 0.05.
3. Results
All the 15 enrolled PDpatients (12males,mean age± SD 67±9
years, disease duration 5 ± 3 years) completed the study. At
T0, 1 patient was free from PDmedication, 1 was treated with
selegiline, and 13 were treated with LD (mean daily dose ± SD
= 333 ± 162mg), in combination with rasagiline in 4 patients
(Supplementary Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/3724148).
At T1, 12 patients were taking the maximal rotigotine
dose of 8mg/24 h. Patient 1 referred adequate improvement
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Table 1: Scale results before (T0) and during (T1) rotigotine
treatment.
Scale T0 T1 𝑝
UPDRS-III∗ 26 (18–41) 22 (11–39) 0.018
H&Y 2 (2-2) 2 (2-2) 0.083
MMSE 28 (27–30) 30 (27–30) 0.121
PDSS-2∗ 20 (16–30) 9 (4–20) 0.001
ESS 5 (4–6) 2 (3–7) 0.937
PDQ-39∗ 34 (19–55) 29 (18–42) 0.016
BDI 7 (3–12) 6 (5–13) 0.977
UPDRS-III = Unified Parkinson’s Disease (PD) Rating Scale-part III; H&Y =
Hoehn and Yahr Score; MMSE = Mini Mental State Examination; PDSS-2 =
PD Sleep Scale-2; ESS = Epworth Sleep Scale; PDQ-39 = PD Questionnaire-
39; BDI = Beck Depression Inventory. Data are expressed as medians and
25th–75th percentiles. ∗ = statistical significance 𝑝 ≤ 0.05.
of motor symptoms at 6mg/24 h. Two patients decreased the
dose during the titration phase to 6mg/24 h (patient 10) and
4mg/24 h (patient 15) as they experienced adverse events
at higher dose (compulsive sexual behavior and irritability,
resp.).
At T1 compared to T0 significant improvements of
motor performance (UPDRS-III) and self-reported sleep
complaints (PDSS-2) were observed (Table 1). Single item
analysis of PDSS-2 showed a significant improvement in 9
out of 15 items including those exploring quality of sleep,
motor symptoms at night, pain, and nocturia (Supplementary
Table 2).
Four patients (2, 3, 7, and 11) reported RLS at T0 and
a significant decrease in RLS severity while on rotigotine
treatment (RLS severity at T0 is 31, 29, 36, and 21 and at T1
is 21, 18, 29, and 0). Ten patients had a positive questionnaire
for RBD. Four out of the 6 patients reporting at least one RBD
episode/week at T0 referred a RBD frequency decrease at T1.
ESS score was globally unchanged after rotigotine treat-
ment (Table 1).
Actigraphic and sleep diary data are reported in Tables
2 and 3. During the nocturnal period at T1, we observed a
significant reduction in mean duration of wake episodes and
ACmean. When considering only the ten patients showing
pathological SE (≤85%) at T0, we also observed a significant
improvement in SE and a significant reduction in WASO,
mean duration of wake episodes, ACmean, and ACmedian
at T1.
Nights of good sleep perweekwere significantly increased
and number and duration of nocturnal awakenings signif-
icantly decreased under rotigotine according to patients’
diaries.
During the diurnal period actigraphic recording showed
a significant reduction in number and duration of sleep
episodes at T1, while only reduction in the number of sleep
episodes emerged from patients’ diaries.
Finally MMSE score, H&Y Score, and BDI score were not
significantly different at T1 while a significant improvement
of QoL was observed (Table 1).
4. Discussion
In this open-label pilot study we demonstrated, by means
of actigraphic recordings, that the introduction of rotigotine
was objectively associated with a significant reduction in
motor activity and mean duration of wake episodes during
nocturnal sleep in PD patients with self-reported sleep com-
plaints. In patients with pathological SE at baseline (≤85%)
[21, 22], rotigotine also significantly improved SE andWASO
and further reduced motor activity and mean duration of
wake episodes during sleep.
In agreement with previous studies we also confirmed
that rotigotine improves perceived sleep quality in PD
patients [4–6] and is associated with amelioration of QoL.
According to our actigraphic and patients’ reported
results, rotigotine’s effect on sleep disturbances may depend
on several factors: (1) reduction in motor activity during
sleep, which could be related to the need to move limbs
due to restlessness or to painful posturing, which may
cause awakening or arousal from sleep; (2) improvement
of a coexisting sleep disorder like RLS; (3) improvement of
nocturia and painful posturing as what emerged from PDSS-
2. Rotigotine may also contribute to the reduction of the
number of spontaneous or movement related arousal times
during sleep [23], which could be increased inPDpatients [3].
This may explain the subjective sleep quality improvement in
patients presenting normal SE at T0 and T1.
Rotigotine was well tolerated in this study. Sleep attacks
or worsening of daytime sleepiness was not observed under
treatment, during which on the contrary we found a decrease
in number and duration of daytime sleep episodes.This result
is clinically significant only for the duration of sleep episodes
while their number was already low before treatment with
rotigotine.
The main limitation of the study is the lack of a placebo
group which does not allow us to evaluate the presence and
magnitude of a placebo effect. However our subjective data
are in agreement with the previous randomized placebo-
controlled study showing a subjective sleep improvement
with rotigotine [4].
5. Conclusions
We demonstrated for the first time by means of objective
measurements a positive effect of rotigotine on nocturnal and
diurnal sleep disturbances in PD patients with self-reported
sleep complaints. Larger randomized placebo-controlled
studies with actigraphic or polysomnographic recordings are
warranted to confirm these data and define the effect of
rotigotine on sleep fragmentation and arousal from sleep.
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Table 2: Actigraphic and sleep diary results before (T0) and during (T1) rotigotine treatment.
T0 T1 𝑝
Nocturnal actigraphic data
SL (min) 42 (15–65) 15 (8–40) 0.363
TST (min) 373 (321–424) 379 (298–399) 0.609
SE (%) 82 (64–87) 82 (71–88) 0.118
WASO (min) 122 (65–169) 83 (66–136) 0.069
N. of wake episodes 19 (11–21) 19 (16–26) 0.164
Mean duration of wake episodes (min)∗ 9 (6–12) 7 (4–8) 0.002
ACmean (counts/min)∗ 37 (26–51) 29 (24–41) 0.020
ACmedian (counts/min) 5 (0–27) 4 (0–16) 0.077
ACindex 53 (39–75) 54 (39–71) 0.349
Nocturnal sleep diary data
N. of good nights/week∗ 3 (0–4) 4 (3–6) 0.004
N. of wake episodes∗ 1 (0–2) 0 (0-1) 0.003
Total duration of wake episodes (min)∗ 29 (5–60) 0 (0–38) 0.002
Diurnal actigraphic data
N. of sleep episodes∗ 1 (1-2) 1 (1-1) 0.014
Total duration of sleep episodes (min)∗ 70 (36–155) 57 (27–77) 0.011
Diurnal sleep diary data
N. of sleep episodes∗ 1 (0-1) 0 (0-1) 0.046
Total duration of sleep episodes (min) 51 (17–94) 26 (9–69) 0.249
SL = sleep latency; min = minutes; TST = total sleep time; SE = sleep efficiency; WASO = wake after sleep onset; N. = number; ACmean = activity mean score;
ACmedian = activity median score; ACindex = activity index. Data are expressed as median (25th–75th percentiles). ∗ = statistical significance 𝑝 ≤ 0.05.
Table 3: Nocturnal actigraphic results before (T0) and during (T1) rotigotine treatment in 10 patients with sleep efficiency ≤ 85% at T0.
Scale T0 T1 𝑝
SL (min) 47 (23–66) 24 (7–40) 0.241
TST (min) 343 (289–373) 330 (286–397) 0.508
SE (%)∗ 68 (51–82) 73 (69–83) 0.017
WASO (min)∗ 147 (114–215) 109 (81–152) 0.013
Number of wake episodes 20 (19–22) 21 (16–28) 0.646
Mean duration of wake episodes (min)∗ 11 (8–14) 7 (5–9) 0.005
ACmean∗ 47 (36–69) 35 (28–44) 0.005
ACmedian∗ 11 (5–30) 8 (0–17) 0.028
ACindex 64 (50–79) 65 (43–73) 0.114
SL = sleep latency; min = minutes; TST = total sleep time; SE = sleep efficiency; WASO = wake after sleep onset; ACmean = activity mean score; ACmedian =
activity median score; ACindex = activity index. Data are expressed as median (25th–75th percentiles). ∗ = 𝑝 ≤ 0.05.
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